Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Место защищенных пенициллинов в терапии обострений хронической обструктивной болезни легких
Место защищенных пенициллинов в терапии обострений хронической обструктивной болезни легких
А.Н.Цой, Н.Б.Лазарева. Место защищенных пенициллинов в терапии обострений хронической обструктивной болезни легких. Consilium Medicum. Пульмонология (Прил.). 2009; 1: 31-33.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Miravitlles M, Zalacain R, Murio C et al. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin Drug Invest 2003; 23: 439–50.
2. Miravitlles M, Torres A. Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J 2004; 24: 896–7.
3. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001; 17: 995–1007.
4. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333–8.
5. Anthonison NR. The British hypothesis revisited. Eur Respir J 2004; 23: 657–8.
6. Sethi S, Evans N, Grant B, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–71.
7. Stockley RA, O'Brien C, Pye A et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2001; 117: 1638–45.
8. Bandi V, Jakubowycz M, Kinyon C et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37: 69–75.
9. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229–46.
10. Johnson DM, Biedenbach DJ, Beach ML et al. Antimicrobial activity and in vitro susceptibility testdevelopment for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37: 99–105.
11. Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000–2002). Diagn Microbiol Infect Dis 2003; 47: 515–25.
12. Ram FS, Rodriguez-Roisin R, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD004403.
13. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006) Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.org.
14. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116 (1): 40–6.
15. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS positionpaper. Eur Respir J 2004; 23 (6): 932–46.
16. Anzeuto A, Bishai WR, Pottumarthy S. Role of oral extendedspectrum cephems in the treatment of acute exacerbation of chronic bronchitis: focus on cefdinir. 2006; 118 (Suppl. 7A): 39S–44.
2. Miravitlles M, Torres A. Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J 2004; 24: 896–7.
3. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001; 17: 995–1007.
4. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333–8.
5. Anthonison NR. The British hypothesis revisited. Eur Respir J 2004; 23: 657–8.
6. Sethi S, Evans N, Grant B, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–71.
7. Stockley RA, O'Brien C, Pye A et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2001; 117: 1638–45.
8. Bandi V, Jakubowycz M, Kinyon C et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37: 69–75.
9. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229–46.
10. Johnson DM, Biedenbach DJ, Beach ML et al. Antimicrobial activity and in vitro susceptibility testdevelopment for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37: 99–105.
11. Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000–2002). Diagn Microbiol Infect Dis 2003; 47: 515–25.
12. Ram FS, Rodriguez-Roisin R, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD004403.
13. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006) Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.org.
14. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116 (1): 40–6.
15. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS positionpaper. Eur Respir J 2004; 23 (6): 932–46.
16. Anzeuto A, Bishai WR, Pottumarthy S. Role of oral extendedspectrum cephems in the treatment of acute exacerbation of chronic bronchitis: focus on cefdinir. 2006; 118 (Suppl. 7A): 39S–44.
Авторы
А.Н.Цой, Н.Б.Лазарева
ГОУ ВПО Московская медицинская академия им. И.М.Сеченова
ГОУ ВПО Московская медицинская академия им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.